Pfizer: Potential cachexia cancer drug shows life-saving promise
A drug that could reduce the risk of death in cancer patients is showing good promise during its second phase of clinical tests, drug-maker Pfizer announced Saturday.
Drug breakthrough provides new hope for cancer patients with cachexia
Researchers discovered a drug that safely and effectively helped cancer patients when they suffered from cachexia (ku-KEK-see-uh), a common condition related to cancer that involves weight loss and muscle wasting.
ESMO 2024: Pfizer’s cachexia drug provides meaningful weight gain
Ponsegromab reached a clinically meaningful 5.6% mean weight increase at the high dose level in patients with cancer cachexia.
Pfizer drug shows promise in cancer-related condition that causes weight loss and weakness
Pfizer reported at #ESMO that an experimental antibody helped cancer patients with a condition known as cachexia.
Pfizer Drug Treating Fatal Weight Loss in Cancer Patients Found Effective
Pharma giant Pfizer said that a drug aimed at helping cancer patients losing appetite and muscle mass showed positive results in a Phase 2 trial.
New Cancer Drug Boosts Weight, Activity in Patients
Researchers discovered a drug that safely and effectively helped cancer patients when they suffered from cachexia (ku-KEK-see-uh), a common condition
Pfizer says its experimental drug for deadly condition that causes appetite and weight loss in cancer patients shows positive trial results
The results could pave the way for Pfizer’s drug ponsegromab to become the first-ever approved treatment specifically for cancer cachexia.
ESMO: Pfizer sees weight gain in cancer patients, aims to enter phase 3 in 2025
Cancer patients with wasting syndrome have gained weight after taking Pfizer’s anti-GDF-15 antibody in a midphase study, emboldening the Big Pharma to target a 2025 start date for its pivotal trial program.
Pfizer Drug Helped Cancer Patients Regain Weight, Study Shows
Pfizer Inc.’s experimental drug for cancer weight loss was shown to help patients regain weight in a mid-stage study, offering fresh promise for treating the dangerous muscle-wasting condition.
Pfizer therapy succeeds in mid-stage trial for cancer-related weight loss
Pfizer's (PFE) experimental therapy for cancer related weight loss, ponsegromab, meets the primary endpoint in Phase 2 trial. Read more here.
KOIN Portland on MSN8h
New OHSU study shows promise in treating ‘urgent, unmet need’ in cancer patients
A new study from OHSU is claiming to show promise in the treatment of what they are calling an "urgent, unmet need" in cancer ...
Science Daily1d
New cancer cachexia treatment boosts weight gain and patient activity
A nationwide clinical trial shows positive results for cancer patients with this common wasting syndrome. Researchers discovered a drug that safely and effectively helped cancer patients when they ...
Pfizer Advances On Its Cancer Journey
Pfizer Inc (NYSE: PFE) presented positive trial data for experimental drug designed for patients suffering from cancer ...
Optimistic Buy Rating for Artelo Biosciences Amidst Growing Focus on Cancer Cachexia Therapies
Maxim Group analyst Jason McCarthy maintained a Buy rating on Artelo Biosciences (ARTL – Research Report) yesterday and set a price ...
Medpage Today on MSN3d
Novel Agent Effective for Cancer Wasting Disorder
Patients with cancer cachexia and an elevated level of growth differentiation factor 15 (GDF-15) achieved significant ...